Frank Weidemann1, Dan Liu2, Kai Hu2, Cristiane Florescu3, Markus Niemann2, Sebastian Herrmann2, Bastian Kramer2, Stephan Klebe4, Kathrin Doppler4, Nurcan Üçeyler4, Christian Oliver Ritter5, Georg Ertl2, Stefan Störk2. 1. Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; Medical Clinic II, Katharinen-Hospital, Unna, Germany. Electronic address: f.weidemann@katharinen-hospital.de. 2. Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 3. Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 4. Department of Neurology, University of Würzburg, Würzburg, Germany. 5. Department of Radiology, University of Würzburg, Würzburg, Germany.
Abstract
BACKGROUND: Patients with autosomal-recessively inherited Friedreich's ataxia (FA) may develop a hypertrophic cardiomyopathy (CM), which potentially progresses towards a life-limiting problem. The typical features of this CM and the sequence of progression are widely unknown. METHODS: Thirty-two consecutive patients with genetically confirmed FA were included. All patients received resting electrocardiogram (ECG), 24-hour Holter-ECG, echocardiography with speckle tracking imaging, cardiac magnetic resonance imaging (cMRI) with late enhancement imaging (for replacement fibrosis), and measurement of high-sensitive troponin-T (hsTNT). In addition, morphological parameters were retrospectively compared to data obtained five years before. RESULTS: Based on criteria comprising ejection fraction (<55%), left ventricular end-diastolic posterior wall thickness (LVPWT ≥ 11 mm), fibrosis on cMRI, hsTNT ≥ 14 ng/ml, or T-wave-inversion, in all but two patients a CM could be detected (94%). Using these criteria we propose the following staging: a) mild CM (n=5, 16%; T-wave-inversion only); b) intermediate CM (n=4, 13%; T-wave-inversion with hypertrophy but no fibrosis); c) severe CM (n=13, 41%; fibrosis with raised hsTNT); and d) end-stage CM (n=8; 25%; ejection-fraction<55%). All patients with end-stage CM also showed fibrosis on cMRI, T-wave-inversion, marked elevation in hsTNT, and a decrease in LVPWT during the last five years (from 10.7 ± 1.2mm to 9.5 ± 1.3mm, p=0.025). In addition, 38% suffered from supraventricular tachycardia on Holter-ECG. CONCLUSIONS: A comprehensive cardiac assessment will unravel established CM in almost all patients with FA with electrocardiographic abnormalities as earliest signs. Advanced stages can be characterized by elevated hsTNT and replacement fibrosis leading to recession of hypertrophy, reduction of global myocardial function, and electrical instability.
BACKGROUND:Patients with autosomal-recessively inherited Friedreich's ataxia (FA) may develop a hypertrophic cardiomyopathy (CM), which potentially progresses towards a life-limiting problem. The typical features of this CM and the sequence of progression are widely unknown. METHODS: Thirty-two consecutive patients with genetically confirmed FA were included. All patients received resting electrocardiogram (ECG), 24-hour Holter-ECG, echocardiography with speckle tracking imaging, cardiac magnetic resonance imaging (cMRI) with late enhancement imaging (for replacement fibrosis), and measurement of high-sensitive troponin-T (hsTNT). In addition, morphological parameters were retrospectively compared to data obtained five years before. RESULTS: Based on criteria comprising ejection fraction (<55%), left ventricular end-diastolic posterior wall thickness (LVPWT ≥ 11 mm), fibrosis on cMRI, hsTNT ≥ 14 ng/ml, or T-wave-inversion, in all but two patients a CM could be detected (94%). Using these criteria we propose the following staging: a) mild CM (n=5, 16%; T-wave-inversion only); b) intermediate CM (n=4, 13%; T-wave-inversion with hypertrophy but no fibrosis); c) severe CM (n=13, 41%; fibrosis with raised hsTNT); and d) end-stage CM (n=8; 25%; ejection-fraction<55%). All patients with end-stage CM also showed fibrosis on cMRI, T-wave-inversion, marked elevation in hsTNT, and a decrease in LVPWT during the last five years (from 10.7 ± 1.2mm to 9.5 ± 1.3mm, p=0.025). In addition, 38% suffered from supraventricular tachycardia on Holter-ECG. CONCLUSIONS: A comprehensive cardiac assessment will unravel established CM in almost all patients with FA with electrocardiographic abnormalities as earliest signs. Advanced stages can be characterized by elevated hsTNT and replacement fibrosis leading to recession of hypertrophy, reduction of global myocardial function, and electrical instability.
Authors: Andy On-Tik Wong; Gabriel Wong; Michael Shen; Maggie Zi-Ying Chow; Wan Wai Tse; Bimal Gurung; Suet Yee Mak; Deborah K Lieu; Kevin D Costa; Camie W Chan; Alain Martelli; Joseph F Nabhan; Ronald A Li Journal: Stem Cell Res Ther Date: 2019-07-08 Impact factor: 6.832
Authors: Roger E Peverill; Giovanni Romanelli; Lesley Donelan; Rhonda Hassam; Louise A Corben; Martin B Delatycki Journal: PLoS One Date: 2019-11-13 Impact factor: 3.240
Authors: Alexandru Al Ecovoiu; Attila Cristian Ratiu; Miruna Mihaela Micheu; Mariana Carmen Chifiriuc Journal: Int J Mol Sci Date: 2022-02-27 Impact factor: 5.923
Authors: Gabrielle Norrish; Thomas Rance; Elena Montanes; Ella Field; Elspeth Brown; Vinay Bhole; Graham Stuart; Orhan Uzun; Karen A McLeod; Maria Ilina; Satish Adwani; Piers Daubeney; Grazia Delle Donne; Katie Linter; Caroline B Jones; Tara Bharucha; Elena Cervi; Juan Pablo Kaski Journal: Arch Dis Child Date: 2021-10-05 Impact factor: 3.791